Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2026-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
• Collaborator: Shanghai Pharmaceuticals Holding Co., Ltd
• Treatments: Paclitaxel

Criteria

Inclusion Criteria:

1. Women or men aged 18 -75 years

2. Locally advanced or metastatic triple negative breast cancer (TNBC)

3. No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC

4. ECOG performance status of 0 or 1

5. Patient must have measurable or evaluable disease as defined by RECIST v1.1. Measurable lesions will be confirmed by radiographic imaging (CT or MRI)

Exclusion Criteria:

1. Prior treatment with anti-ROR1 or anti-Wnt5a therapeutic antibodies

2. Spinal cord compression not definitively treated with surgery and/or radiation prior to study entry

3. Known central nervous system (CNS) disease

4. Uncontrolled pleural effusion, pericardial effusion, or ascites Patients

5. Uncontrolled tumor-related pain prior to study entry

6. The patient has a history of another malignancy within 5 years prior to study entry, except adequately treated non-melanotic skin cancer, carcinoma in situ of the cervix or Papillary carcinoma of the thyroid

7. Pregnancy or lactation